Skip to main content
. Author manuscript; available in PMC: 2011 Oct 4.
Published in final edited form as: Virology. 2010 May 8;404(1):5–20. doi: 10.1016/j.virol.2010.04.008

Table-1.

Table-1A Virologic and clinical characteristics of subject WC4
Tropism of 6.6kb
sequences, Nb 		Genotypic Resistance Associated Mutations
Sample IDa / Variant R5 X4 Protease RT Resistance interpretation
WC4P-0995: VL, log10 5.7; CD4, 28 cells/mm3; ART prescribed, None
9 3
  WC4P-0995-3 R5 None L74V ddI-R
  WC4P-0995-8 R5 None L74V ddI-R
  WC4P-0995-9 R5 None T69D, V179A ddC-R
  WC4P-0995-5 X4 None L74V ddI-R
  WC4P-0995-6 X4 None None No resistance
WC4P-0296: VL, log10 4.94; CD4, 42 cells/mm3; ART prescribed, 3TC
2 2
  WC4P-0296-1 R5 None None No resistance
  WC4P-0296-3 R5 None T69A, M184V 3TC-R
  WC4P-0296-2 X4 None L74V, M184V ddI-R, 3TC-R
  WC4P-0296-4 X4 None None No resistance
WC4P-0896: VL, log10 5.27; CD4, 25 cells/mm3; ART prescribed, d4T, 3TC
6 0
  WC4P-0896-3 R5 None L74V, M184V ddI-R, 3TC-R
  WC4P-0896-4 R5 None T69A No resistance
  WC4P-0896-5 R5 None T69D ddC-R
  WC4P-0896-8 R5 None L74V, M184V ddI-R, 3TC-R
WC4P-0397: VL, log10 5.61; CD4, 10 cells/mm3; ART prescribed, d4T, 3TC, IDV
6 3
  WC4P-0397-1 R5 None None No resistance
  WC4P-0397-5 R5 None T69A No resistance
  WC4P-0397-6 R5 None None No resistance
  WC4P-0397-4 X4 None None No resistance
  WC4P-0397-8 X4 None None No resistance
WC4P0897: VL, log10 5.81; CD4, 0 cells/mm3; ART prescribed, AZT, 3TC, NFV
6 3
  WC4P-0897-1 R5 None None No resistance
  WC4P-0897-3 R5 None None No resistance
  WC4P-0897-5 R5 None None No resistance
  WC4P-0897-10 X4 None None No resistance
  WC4P-0897-14 X4 None None No resistance
WC4P-0798: VL, log10 4.75; CD4, 97 cells/mm3; ART prescribed, AZT, 3TC, NFV
2 6
  WC4P-0798-3 R5 D30N, N88D K70R, M184V NFV-R, 3TC-R
  WC4P-0798-8 R5 D30N, N88D K70R, M184V NFV-R, 3TC-R
  WC4P-0798-1 X4 D30N, N88D K70R, M184V NFV-R, 3TC-R
  WC4P-0798-5 X4 D30N, N88D M184V NFV-R, 3TC-R
WC4P-0399: VL, log10 5.63; CD4, 108 cells/mm3 ART prescribed, AZT, 3TC NFV
2 8
  WC4P-0399-3 R5 N88D D67N, K70R, K103N,
M184V, T215A, K219Q		 AZT-REVT, 3TC-R, NFV-R, NNRTI-R
  WC4P-0399-11 R5 N88D D67N, K70R, M184V, K219Q AZT-REVT, 3TC-R, NFV-R
  WC4P-0399-2 X4 D30N, N88D K70R, M184V 3TC-R, NFV-R
  WC4P-0399-5 X4 N88D K103N, M184V 3TC-R, NFV-R, NNRTI-R
  WC4P-0399-10 X4 N88D K70R, V108I, M184V 3TC-R, NFV-R, NNRTI-LLR
WC4P-1299: VL, log10 5.5; CD4, 58 cells/mm3; ART prescribed, ABC, RTV, IDV, NVP
8 6
  WC4P-1299-1 R5 None None No Resistance
  WC4P-1299-16 R5 None None No Resistance
  WC4P-1299-3 X4 None None No Resistance
  WC4P-1299-4 X4 None None No Resistance
  WC4P-1299-5 X4 None None No Resistance
WC4P-1000: VL, log10 5.87; CD4, NAc; ART prescribed, ABC, d4T, RTV, IDV, NVP
8 2
  WC4P-1000-1 R5 None K103N NNRTI-R
  WC4P-1000-2 R5 None K103N NNRTI-R
  WC4P-1000-5 R5 None K103N, K219Q NNRTI-R
  WC4P-1000-6 R5 None K103N NNRTI-R
  WC4P-1000-7 R5 None K103N NNRTI-R
  WC4P-1000-10 R5 None K103N NNRTI-R
  WC4P-1000-8 X4 None K103N NNRTI-R
Table-1B Virologic and clinical characteristics of subject WC2
Tropism of 6.6kb
sequences, Nb 		Genotypic Resistance Associated Mutations
Sample IDa / Variant R5 X4 Protease RT Resistance Interpretation
WC2P-0795: VL, log10 5.28; CD4, 6 cells/mm3; ART prescribed, None
8 1
  WC2P-0795-4 R5 None T69N, K70G ddC-R
  WC2P-0795-8 R5 None T69N, K70G ddC-R
  WC2P-0795-9 X4 None T69N, K70T ddC-R
WC2P-0296: VL, log10 4.88; CD4, 3 cells/mm3; ART prescribed, None
13 1
  WC2P-0296-1 R5 None T69D ddC-R
  WC2P-0296-2 R5 None T69N ddC-R
  WC2P-0296-15 X4 None T69N, V108I ddC-R,NNRTI-LLR
WC2P-0896: VL, log10 4.7; CD4, 74 cells/mm3; ART prescribed, AZT, 3TC
2 2
  WC2P-0896-1 R5 None T69N, K70R, M184V ddC-R, 3TC-R
  WC2P-0896-2 R5 None T69N, K70R, M184V ddC-R, 3TC-R
  WC2P-0896-3 X4 None T69N, K70R, M184V ddC-R, 3TC-R
  WC2P-0896-4 X4 None T69N, K70R, M184V ddC-R, 3TC-R
WC2P-0897: VL, log10 4.74; CD4, 90 cells/mm3; ART prescribed, d4T, 3TC
3 4
  WC2P-0897-3 R5 None D67N, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
  WC2P-0897-6 R5 None D67N, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
  WC2P-0897-7 R5 None D67N, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
  WC2P-0897-1 X4 None T69N, K70R, M184V ddC-R, 3TC-R
  WC2P-0897-2 X4 None T69N, K70R, M184V ddC-R, 3TC-R
  WC2P-0897-4 X4 None D67N, T69N, K70R, V108I, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R, NNRTI-LLR
  WC2P-0897-5 X4 None D67N, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
WC2P-1297: VL, log10 5.43; CD4, NAc; ART prescribed, d4T, 3TC, SQV
8 2
  WC2P-1297-1 R5 None D67N, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
  WC2P-1297-2 R5 None D67S, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
  WC2P-1297-5 X4 None D67A, T69N, K70R, V108I, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R, NNRTI-LLR
  WC2P-1297-14 X4 None D67A, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
WC2P-0798: VL, log10 4.64; CD4, 188 cells/mm3; ART prescribed, ddI, NFV
7 3
  WC2P-0798-1 R5 None D67N, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
  WC2P-0798-2 R5 None D67N, T69N, K70R, V118I, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
  WC2P-0798-7 R5 None D67N, T69N, K70R, V108I, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R, NNRTI-LLR
  WC2P-0798-5 X4 None D67N, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
  WC2P-0798-9 X4 None D67N, T69N, K70R, M184V, T215F, K219E AZT/d4T-R, ddC-R, 3TC-R
a

Sample ID: WC stands for Wadsworth Center, numbers indicate patient number, P stands for plasma, numbers following the dash are month and year sample collected; numbers following month and year of sample are variant numbers.

b

Numbers under R5 and X4 columns are the number of R5 and X4 variants as predicted by V3 sequences of the 6.6kb fragment. Sequences of pol and gp120 from the complete 6.6kb fragment were obtained only for those R5 and X4 variants listed.

c

NA, not available

Note. VL, viral load log10 RNA copies/ml; 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; d4T, stavudine; ddC, zalcitabine; ddI, didanosine; IDV, indinavir; NFV, nelfinavir; NVP, nevirapine; RTV, ritonavir; SQV, saquinavir; ART, antiretroviral therapy; NNRTI, non-nucleoside reverse-transcriptase inhibitors; RT, reverse transcriptase; R, high level resistance; LLR, low level resistance; REVT, revertant;